Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Рак желчевыводящей системы

Список литературы

  1. Sheth S., Bedford A., Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. American Journal of Gastroenterology 2000;95:1402– 1410.
  2. Hueman M.T., Vollmer C.M., Pawlik T.M. Evolving treatment strategies for gallbladder cancer. Annals of Surgical Oncology 2009;16:2101–2115.
  3. Hundal R., Shaffer E.A. Gallbladder cancer: epidemiology and outcome. ClinicalEpidemiology 2014;6:99–109.
  4. Patel T. Cholangiocarcinoma – controversies and challenges. Nature Reviews Gastroenterology Hepatology 2011;8:189–200.
  5. Yamamoto S., Kubo S., Hai S., et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Science 2004;95:592–595.
  6. Welzel T.M., Graubard B.I., El-Serag H.B., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clinical Gastroenterology Hepatology 2007;5:1221–1228.
  7. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2019. 250 с.
  8. Zhu A.X., Hong T.S., Hezel A.F., Kooby D.A. Current management of gallbladder carcinoma. Oncologist 2010;15:168–181.
  9. Valle1 J. W., Borbath I., Khan S. A., et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2016;27(suppl.5):v28– v37.Doi:10.1093/annonc/mdw324.
  10. DeOliveira M.L., Cunningham S.C., Cameron J.L., et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Annals of Surgery2007;245:755–762.
  11. Lim J.H. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. American Journal ofRoentgenology2003;181:819–827.
  12. Hawkins W.G., DeMatteo R.P., Jarnagin W.R., et al. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Annals of Surgical Oncology 2004;11:310–315.
  13. Jarnagin W.R., Ruo L., Little S.A., et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689–1700.
  14. Furlan A., Ferris J.V., Hosseinzadeh K., Borhani A.A. Gallbladder carcinoma update: multimodality imaging evaluation, staging, and treatment options. American Journal of Roentgenology2008;191:1440–1447.
  15. Miller G., Schwartz L.H., D"Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surgical Oncology Clinics of North America2007;16:343–368.
  16. Levy A.D., Murakata L.A., Rohrmann C.A., Jr. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics2001;21:295–314.
  17. Petrowsky H., Wildbrett P., Husarik D.B., et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. Journal of Hepatology2006;45(1):43–50.
  18. Khan Z.S., Livingston E.H., Huerta S. Reassessing the need for prophylactic surgery in patients with porcelain gallbladder: case series and systematic review of the literature. Archives of Surgery2011;146:1143–1147.
  19. Eckel F., Brunner T. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Jelic Annals of Oncology 2011;22(suppl.6):vi40–vi44. Doi:10.1093/annonc/mdr375.
  20. Zografos G., Farfaras A., Zagouri F., et al. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreatic Diseases International2011;10(1):10–20.
  21. Nagino M., Kamiya J., Nishio H., et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Annals of Surgery2006;243:364–372.
  22. Regimbeau J.M., Fuks D., Le Treut Y.-P.,et al. Surgery for Hilar Cholangiocarcinoma: A Multi- institutional Update on Practice and Outcome by the AFC-HC Study Group. Journal of Gastrointestinal Surgery2011;15:480–488.
  23. Coburn N.G., Cleary S.P., Tan J.C., Law C.H. Surgery for gallbladder cancer: a population-based analysis. Journal of the American College of Surgeons2008;207:371–382.
  24. Downing S.R., Cadogan K.A., Ortega G., et al. Early-stage gallbladder cancer in the surveillance, epidemiology, and end results database: Effect of extended surgical resection. Archives of Surgery2011;146:734–738.
  25. Goetze T.O., Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Annals of Surgery2008;247:104–108.
  26. Murakami Y., Uemura K., SudoT., et al. Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. Annals of Surgical Oncology2011;18:651– 658.
  27. Meyer C.G., Penn I., James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation2000;69:1633–1637.
  28. Zografos G., Farfaras A., Zagouri F., et al. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreatic Diseases International2011;10(1):10–20.
  29. Neuhaus P., Jonas S., Settmacher U., et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbeck’s Archives of Surgery2003;388:194–200.
  30. Nagino M., Kamiya J., Arai T., et al. ‘Anatomic’ right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Annals of Surgery 2006;243:28–32.
  31. Бредер В.В., Косырев В.Ю., Ледин Е.В. Практические рекомендации по лекарственному лечению билиарного рака. RUSSCO 2017;3(suppl.2):352–366. Doi:10.18027/2224–5057–2017– 7–3s2–352–366
  32. Benson A.B., Michael I. D’Angelica M.I., Abbott D., et al. Hepatobiliary Cancers. NCCN Clinical Practice Guidelines in Oncology 2018;1:1–140.
  33. Ma N., Cheng H., Qin B., et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta- analysis. BMC Cancer 2015;15:615.
  34. Ben-Josef E., Guthrie K.A., El-Khoueiry A.B., et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of Clinical Oncology2015;33(24):2617–2622.
  35. Fisher S.B., Patel S.H., Kooby D.A., et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford) 2012;14:514–522.
  36. Hyder O., Hatzaras I., Sotiropoulos G.C., et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013;153:811–818.
  37. Murakami Y., Uemura K., Sudo T., et al. Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. Annals of Surgical Oncology 2011;18:651– 658
  38. Kelley S.T., Bloomston M., Serafini F., et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. The American Surgeon 2004;70:743–749.
  39. Cereda S., Belli C., Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World Journal of Gastroenterology 2012;18:2591–2596.
  40. Mambrini A., Guglielmi A., Pacetti P., et al. Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Research2007;27: 3009–3013.
  41. Shitara K., Ikami I., Munakata M., et al. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. Clinical Oncology (R CollRadiol) 2008;20:241–246.
  42. Inaba Y., Arai Y., Yamaura H., et al. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG- 0301). American Journal of Clinical Oncology 2011;34:58–62.
  43. Kemeny N.E., Schwartz L., Gonen M., et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology2011;80:153–159.
  44. Boehm L.M., Jayakrishnan T.T., Miura J.T., et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of Surgical Oncology2015;111:213–220.
  45. Ortner M.E., Caca K., Berr F., et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125:1355–1363.
  46. Zoepf T., Jakobs R., Arnold J.C., et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. American Journal of Gastroenterology 2005;100:2426– 2430.
  47. Ghafoori A.P., Nelson J.W., Willett C.G., et al. Radiotherapy in the Treatment of Patients with Unresectable Extrahepatic Cholangiocarcinoma. International Journal of Radiation Oncology, Biology, Physics2011;81(3):654–659.
  48. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. British Journal of Cancer 2007;96:896–902.
  49. Yonemoto N., Furuse J., Okusaka T., et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Japanese Journal of Clinical Oncology 2007;37:843–851.
  50. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine2010;362:1273–1281.
  51. Lamarca A., Palmer D.H., Wasan H.S., et al. of the Advanced Biliary Cancer (ABC) Working Group.ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.J Clin Oncol 2019;37(suppl.; abstr. 4003)
  52. Cong W.M. Surgical pathology of hepatobiliary tumors. Springer 2017:1–372.
  53. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D; ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v28-v37.
  54. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105.
  55. Søreide K. et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy //British Journal of Surgery. – 2019. – Т. 106. – №. 1. – С. 32-45.
  56. Asher A., Ng A., Engle J. Principles of Cancer Rehabilitation //Cardio-Oncology: Principles, Prevention and Management. – Elsevier Inc., 2016. – С. 279-296.
  57. Завражнов А. А. и др. Значение малоинвазивных методов декомпрессии желчных протоков в лечении больных с механической желтухой //Журнал им. НВ Склифосовского Неотложная медицинская помощь. – 2012. – №. 2.
  58. Tella S. H. et al. Second-line therapies in advanced biliary tract cancers //The Lancet Oncology. – 2020. – Т. 21. – №. 1. – С. e29-e41.
  59. Dodagoudar C. et al. FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients //Japanese journal of clinical oncology. – 2016. – Т. 46. – №. 1. – С. 57-62.
  60. Knox J. J. et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial //Journal of Clinical Oncology. – 2005. – Т. 23. – №. 10. – С. 2332-2338.
  61. Jang J. S. et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial //Cancer chemotherapy and pharmacology. – 2010. – Т. 65. – №. 4. – С. 641-647.
  62. Kim S. T. et al. Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial //Journal of Cancer. – 2019. – Т. 10. – №. 25. – С. 6185-6190.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*